Granted Patent
B2
US 12,558,349 · App. 18/324,754 · Granted Feb 24, 2026
Methods of treating infections in overweight and obese patients using antibiotics
Assignee:
MELINTA SUBSIDIARY CORP.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present disclosure relates generally to methods of treating infections in overweight or obese patients using antibiotics.
Claims (15)
1 . A method of treating an Acute Bacterial Skin and Skin Structure Infection (ABSSSI) in an overweight or obese patient in need thereof, the method comprising intravenously (IV) administering to the patient a composition comprising 433 mg of delafloxacin meglumine salt which corresponds to 300 mg of delafloxacin, twice a day.
2 . The method of claim 1 , wherein the overweight or obese patient has a body mass index greater than 25.
3 . The method of claim 2 , wherein the overweight or obese patient has a body mass index greater than or equal to 30.
4 . The method of claim 3 , wherein the overweight or obese patient has a body mass index greater than or equal to 35.
5 . The method of claim 4 , wherein the overweight or obese patient has a body mass index greater than or equal to 40.
6 . The method of claim 1 , wherein the composition further comprises beta-cyclodextrin sulfobutyl ether.
7 . The method of claim 6 , wherein the amount of beta-cyclodextrin sulfobutyl ether is 2400 mg.
8 . The method of claim 1 , wherein the composition further comprises disodium EDTA.
9 . The method of claim 8 , wherein the amount of disodium EDTA is 1.32 mg.
10 . The method of claim 1 , wherein the composition further comprises meglumine.
11 . The method of claim 10 , wherein the amount of meglumine is 58.56 mg.
12 . A method of treating an Acute Bacterial Skin and Skin Structure Infection (ABSSSI) in an overweight or obese patient in need thereof, the method comprising intravenously (IV) administering to the patient twice a day a composition comprising 433 mg of delafloxacin meglumine salt which corresponds to 300 mg of delafloxacin, wherein the composition comprises:
(1) 25 mg/mL of delafloxacin meglumine, calculated as free acid;
(2) 4.88 mg/mL of meglumine; and
(3) 200 mg/mL of beta-cyclodextrin sulfobutyl ether.
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 21, 2026
From: DUFFY, ERIN M.
To: MELINTA THERAPEUTICS, INC.
Reel/Frame 073537/0153 →
CHANGE OF NAME
Recorded Jan 21, 2026
From: MELINTA THERAPEUTICS, INC.
To: MELINTA SUBSIDIARY CORP.
Reel/Frame 073537/0206 →
Continuity (4)
Continuation
14775465
Provisional Application
61790179
· Mar 15, 2013
References Cited (176)
US 4399134A
· Ishikawa et al.
· 1983
[cited by applicant]
US 4552879A
· Ishikawa et al.
· 1985
[cited by applicant]
US 4980470A
· Masuzawa et al.
· 1990
[cited by applicant]
US 4990517A
· Petersen et al.
· 1991
[cited by applicant]
US 5053407A
· Hayakawa et al.
· 1991
[cited by applicant]
US 5607942A
· Petersen et al.
· 1997
[cited by applicant]
US 5633262A
· Hong et al.
· 1997
[cited by applicant]
US 5654435A
· Barbachyn et al.
· 1997
[cited by applicant]
US 5688792A
· Barbachyn et al.
· 1997
[cited by applicant]
US 5776944A
· Hong et al.
· 1998
[cited by applicant]
US 5840684A
· Cooper et al.
· 1998
[cited by applicant]
US 5843889A
· Cooper et al.
· 1998
[cited by applicant]
US 5849752A
· Grunenberg et al.
· 1998
[cited by applicant]
US 5880283A
· Matsumoto et al.
· 1999
[cited by applicant]
US 5912226A
· Baker et al.
· 1999
[cited by applicant]
US 5935952A
· Todo et al.
· 1999
[cited by applicant]
US 5939382A
· Berglund et al.
· 1999
[cited by applicant]
US 5952466A
· Berglund et al.
· 1999
[cited by applicant]
US 5962468A
· Hong et al.
· 1999
[cited by applicant]
US 5977062A
· Cooper et al.
· 1999
[cited by applicant]
US 5994297A
· Nicas et al.
· 1999
[cited by applicant]
US 5998436A
· Yazaki et al.
· 1999
[cited by applicant]
US 5998581A
· Berglund et al.
· 1999
[cited by applicant]
US 6025370A
· Todo et al.
· 2000
[cited by applicant]
US 6133284A
· Yazaki et al.
· 2000
[cited by applicant]
US 6156903A
· Yazaki et al.
· 2000
[cited by applicant]
US 6262071B1
· Crabb et al.
· 2001
[cited by applicant]
US 6331550B1
· Citron et al.
· 2001
[cited by applicant]
US 6340689B1
· Dubois et al.
· 2002
[cited by applicant]
US 6455540B1
· Citron et al.
· 2002
[cited by applicant]
US 6455669B1
· Judice et al.
· 2002
[cited by applicant]
US 6468967B1
· Oleson, Jr. et al.
· 2002
[cited by applicant]
US 6514986B2
· de Souza et al.
· 2003
[cited by applicant]
US 6518242B1
· Chen et al.
· 2003
[cited by applicant]
US 6559305B1
· Bergren
· 2003
[cited by applicant]
US 6589955B2
· Raghavan et al.
· 2003
[cited by applicant]
US 6608078B2
· De Souza et al.
· 2003
[cited by applicant]
US 6620781B2
· Linsell et al.
· 2003
[cited by applicant]
US 6635618B2
· Leadbetter et al.
· 2003
[cited by applicant]
US 6664267B1
· de Souza et al.
· 2003
[cited by applicant]
US 6723734B2
· Kim et al.
· 2004
[cited by applicant]
US 6750224B1
· Patel et al.
· 2004
[cited by applicant]
US 6753333B2
· De Souza et al.
· 2004
[cited by applicant]
US 6770621B2
· Linsell et al.
· 2004
[cited by applicant]
US 6803376B1
· Appelbaum et al.
· 2004
[cited by applicant]
US 6828299B2
· Yang et al.
· 2004
[cited by applicant]
US 6831150B2
· Linsell
· 2004
[cited by applicant]
US 6846939B2
· Nelson et al.
· 2005
[cited by applicant]
US 6852689B2
· Oleson, Jr. et al.
· 2005
[cited by applicant]
US 6858584B2
· Judice et al.
· 2005
[cited by applicant]
US 6872701B2
· Leadbetter et al.
· 2005
[cited by applicant]
US 6872804B2
· Mu
· 2005
[cited by applicant]
US 6878686B2
· Marquess et al.
· 2005
[cited by applicant]
US 6887976B2
· Leadbetter et al.
· 2005
[cited by applicant]
US 6900225B2
· Takemura et al.
· 2005
[cited by applicant]
US 6969726B2
· Lou et al.
· 2005
[cited by applicant]
US 7816376B2
· Schadt et al.
· 2010
[cited by applicant]
US 20040063674A1
· Levy et al.
· 2004
[cited by applicant]
US 20040092490A1
· Draper et al.
· 2004
[cited by applicant]
US 20040142957A1
· Takemura et al.
· 2004
[cited by applicant]
US 20040198715A1
· Cavaleri et al.
· 2004
[cited by applicant]
US 20040220122A1
· Cavaleri et al.
· 2004
[cited by applicant]
US 20040224908A1
· Cavaleri et al.
· 2004
[cited by applicant]
US 20050090433A1
· Colombo et al.
· 2005
[cited by applicant]
US 20070238719A1
· Hopkins et al.
· 2007
[cited by applicant]
US 20070249577A1
· Hopkins et al.
· 2007
[cited by applicant]
US 20120065186A1
· Li et al.
· 2012
[cited by applicant]
JP 2002201191A
· 2002
[cited by applicant]
JP 2002255962A
· 2002
[cited by applicant]
JP 2003096075A
· 2003
[cited by applicant]
JP 2004244380A
· 2004
[cited by applicant]
WO WO9630401A1
· 1996
[cited by applicant]
WO WO9711068A1
· 1997
[cited by applicant]
WO WO9821952A1
· 1998
[cited by applicant]
WO WO9822121A1
· 1998
[cited by applicant]
WO WO9910006A1
· 1999
[cited by applicant]
WO WO00018419A2
· 2000
[cited by applicant]
WO WO0066144A2
· 2000
[cited by applicant]
WO WO0134595A1
· 2001
[cited by applicant]
WO WO2001058876A1
· 2001
[cited by applicant]
WO WO01072738A1
· 2001
[cited by applicant]
WO WO01081350A1
· 2001
[cited by applicant]
WO WO01094342A1
· 2001
[cited by applicant]
WO WO200204406A2
· 2002
[cited by applicant]
WO WO2002042312A1
· 2002
[cited by applicant]
WO WO02072031A2
· 2002
[cited by applicant]
WO WO03005971A2
· 2003
[cited by applicant]
WO WO03029270A2
· 2003
[cited by applicant]
WO WO2003076428A1
· 2003
[cited by applicant]
WO WO03075857A2
· 2003
[cited by applicant]
WO WO2004038000A2
· 2004
[cited by applicant]
WO WO2004038001A2
· 2004
[cited by applicant]
WO WO2004055027A1
· 2004
[cited by applicant]
WO WO2004058261A1
· 2004
[cited by applicant]
WO WO2004058886A1
· 2004
[cited by applicant]
WO WO2004064728A2
· 2004
[cited by applicant]
WO WO2004091513A2
· 2004
[cited by applicant]
WO WO2005009944A1
· 2005
[cited by applicant]
WO WO2005012270A2
· 2005
[cited by applicant]
WO WO2005012271A2
· 2005
[cited by applicant]
WO WO2005019211A2
· 2005
[cited by applicant]
WO WO2005061468A1
· 2005
[cited by applicant]
WO WO2005070904A2
· 2005
[cited by applicant]
WO WO2006015194A2
· 2006
[cited by applicant]
WO WO2006022794A1
· 2006
[cited by applicant]
WO WO2006042034A2
· 2006
[cited by applicant]
WO WO2006110815A1
· 2006
[cited by applicant]
WO WO2010056872A2
· 2010
[cited by applicant]
WO WO2010096551A2
· 2010
[cited by applicant]
WO WO2011146255
· 2011
[cited by applicant]
Barbychan, et al., “Oxazolidinone Structure-Activity Relationships Leading to Linezolid”, Angew. Chem. Int. Ed., vol. 42, pp. 2010-2023 (2003).
[cited by applicant]
Bhalodi, et al., “Pharmacokinetics of Intravenous Linezolid in Moderately to Morbidly Obese Adults,” Antimicrob Agents Chemother., vol. 57, No. 3, pp. 1144-1149 (Mar. 2013, published online Dec. 17, 2012).
[cited by applicant]
Candiani, et al., “In-Vitro and In-Vivo Antibacterial Activity of BI 397, a New Semi-Synthetic Glycopeptide Antibiotic,” J. Antimicrob. Chemotherapy, vol. 44, pp. 179-192 (1999).
[cited by applicant]
Chagnac, et al., “Glomerular Hemodynamics in Severe Obesity,” Am. J. Physiol. Renal. Physiol., vol. 278, pp. F817-F822 (2000).
[cited by applicant]
Falagas, M.E. and Kompoti, M., “Obesity and Infection,” Lancet Infect. Dis., vol. 6(7), pp. 438-446 (2006).
[cited by applicant]
Griffin, et al., “Adverse Renal Consequences of Obesity,” Am. J. Physiol. Renal. Physiol., vol. 294(4), pp. F685-F696 (2008).
[cited by applicant]
Haight, et al., “Synthesis of the Quinolone ABT-492: Crystallizations for Optimal Processing,” Organic Process Research & Development, vol. 10(4), pp. 751-756 (2006).
[cited by applicant]
Hanley, et al., “Effect of Obesity on the Pharmacokinetics of Drugs in Humans,” Clin. Pharmacokinetics, vol. 49(2), pp. 71-87 (2010).
[cited by applicant]
International Search Report and Written Opinion issued by the U.S. Patent and Trademark Office as International Searching Authority for International Application No. PCT/US2014/027220 mailed Jul. 21, 2014 (14 pgs.).
[cited by applicant]
Kurazano, et al., “In Vitro Activities of ME1036 (CP5609), a Novel Parenteral Carbapenem, against Methicillin-Resistant Staphylococci,” Antimicrobial Agents and Chemotherapy, vol. 48, No. 8, pp. 2831-2837 (Aug. 2004).
[cited by applicant]
London, S. “Telavancin Adds Option for Obese Patients with SSSIs,”
[cited by applicant]
Longcor, et al., “Objective Measures of Clinical Efficacy in a Phase 2b Exploratory Study of Delafloxacin Compared to Vancomycin and Linezolid in Adults with Acute Bacterial Skin and Skin Structure Infections (ABSSSI),”…
[cited by applicant]
Mercier, et al., “Pharmacodynamic Evaluation of a New Glycopeptide, LY333328, and In Vitro Activity against
[cited by applicant]
No Author, “A Phase 2 Exploratory Study of Objective Endpoints in Subjects with Acute Bacterial Skin and Skin Structure Infections Treated with Delafloxacin, Vancomycin, or Linezolid,” Adis Clinical Trials Insight (Feb.…
[cited by applicant]
Ogden, et al., “Prevalence of Obesity in the United States 2009-2010,” NCHS Data Brief, No. 82 (Jan. 2012) (8 pgs.).
[cited by applicant]
Otani et al., “In Vitro and In Vivo antibacterial Activities of DK-507k, a Novel Fluoroquinolone,” Antimicrobial Agents and Chemotherapy, vol. 47, No. 12, pp. 3750-3759 (2003).
[cited by applicant]
Pai, et al. “Influence of Morbid Obesity on the Single-Dose Pharmacokinetics of Daptomycin,” Antimicrobial Agents Chemother., vol. 51(8), pp. 2741-2747 (2007).
[cited by applicant]
Reynolds, et al., “Performance of a Vancomycin Dosage Regimen Developed for Obese Patients,” Am J Health Syst Pharm, vol. 69, No. 11, pp. 944-950 (Jun. 1, 2012).
[cited by applicant]
Wurtz, et al., “Antimicrobial Dosing in Obese Patients,” Clin. Infect. Dis., vol. 25, pp. 112-118 (1997).
[cited by applicant]
Rubino, C., et al., “Population pharmacokinetics and pharmacokinetic-pharmacodynamic metrics for delafloxacin,” Clinical Microbiology and Infection, vol. 16, Suppl. 2, 20th ECCMID—Oral Presentations, p. S116, O519 (2010…
[cited by applicant]
O'Riordan, W., et al., “A Comparison of the Efficacy and Safety of Intravenous Followed by Oral Delafloxacin With Vancomycin Plus Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections: A Phas…
[cited by applicant]
Remy, J.M., et al., “Activity of delafloxacin against methicillin-resistant
[cited by applicant]
Burak, E., et al., “Pharmacokinetics and Pharmacodynamics of Delafloxacin in
[cited by applicant]
Lawrence, L. et al., “Metabolism and mass balance of [14C]-Delafloxacin in healthy human volunteers following intravenous administration”, Quotient Bioresearch Ltd, Northants, UK and Rib-X Pharmaceuticals, New Haven, US…
[cited by applicant]
Lemaire, S., et al., “Contrasting Effects of Acidic pH on the Extracellular and Intracellular Activities of the Anti-Gram-Positive Fluoroquinolones Moxifloxacin and Delafloxacin against
[cited by applicant]
Allard et al., “Intravenous ciprofloxacin disposition in obesity,” Clinical Pharmacology and Therapeutics, vol. 54, pp. 368-373 (1993).
[cited by applicant]
Rejection Ruling issued on Mar. 11, 2022 by Chilean Industrial Property Institute (“Chilean Patent Office”) in Chilean Patent Application No. 2015-002759 with English translation (10 total pages).
[cited by applicant]
Communication pursuant to Article 94(3) EPC issued on Apr. 21, 2022 by European Patent Office in European Patent Application No. 14768456.7 (4 total pages).
[cited by applicant]
Technical Examination Report issued on Apr. 27, 2022 by Brazilian Patent Office in Brazlian Patent Application No. BR112015023044-0 with English translation (10 total pages).
[cited by applicant]
Office Action issued on May 17, 2022 by Turkish Patent Office in Turkish Patent Application No. 2015/14167 with English translation (6 total pages).
[cited by applicant]
O'Riordan, W., et al., “Results of a phase 2 study comparing two doses of delafloxacin to tigecycline in adults with complicated skin and skin-structure infections,” 19th European Congress of Clinical Microbiology & Inf…
[cited by applicant]
Roe, et al., “Underdosing of common antibiotics for obese patients in the ED,” American Journal of Emergency Medicine, vol. 30, pp. 1212-1214 (2012).
[cited by applicant]
Cook, et al., “Pharmacokinetics of Intravenous Levofloxacin Administered at 750 Milligrams in Obese Adults,” Antimicrobial Agents and Chemotherapy, vol. 55, No. 7, pp. 3240-3243 (Jul. 1, 2011).
[cited by applicant]
Extended European Search Report issued by the European Patent Office for European Patent Application No. 14768456.7 dated Aug. 22, 2016 (8 pgs.).
[cited by applicant]
Huttunen, et al., “Obesity and the Risk and Outcome of Infection,” International J. of Obesity, vol. 37, No. 3, pp. 333-340 (May 1, 2012).
[cited by applicant]
Kees, et al., “Pharmacokinetics of Moxifloxacin in Plasma and Tissue of Morbidly Obese Patients,” J. of Antimicrobial Chemotherapy, vol. 66, No. 10, pp. 2330-2335 (Jul. 5, 2011).
[cited by applicant]
Kingsley, et al., “A Randomized Double-blind, Phase 2 Study to Evaluate Subjective and Objective Outcomes in Patients with Acute Bacterial Skin and Skin Structure Infections Treated with Delafloxacin, Linezolid or Vanco…
[cited by applicant]
Unfavorable Opinion issued by Brazilian National Institute of Industrial Property in Brazilian Patent Application No. BR112015023044-0 with English translation, Aug. 8, 2022 (12 total pages).
[cited by applicant]
Duffy, E.M., et al., Delafloxacin Chemical Properties Lead to Increased Potency Against Gram-positive Pathogens, Including Quinolone-Resistant Pathogens (II), Poster E-183, 50th ICAAC (Boston, MA, USA), Sep. 12-15, 2010…
[cited by applicant]
Nilius, A.M., “In Vitro Antibacterial Potency and Spectrum of ABT-492, a New Fluoroquinolone,” Antimicrobial Agents and Chemotherapy, vol. 47, No. 10, pp. 3260-3269 (Oct. 2003).
[cited by applicant]
Decision on Appeal issued by Grievance Committee of the Cooperation Council for the Arab States of the Gulf (“GCC Patent Office”) in Gulf Cooperation Council Patent Application No. 26770 with English translation, Oct. 5…
[cited by applicant]
Rejection Decision issued Oct. 6, 2022 by Brazilian Patent Office in Brazilian Patent Application No. BR122022014882-4 with English translation (7 total pages).
[cited by applicant]
Rejection Decision issued Nov. 18, 2022 by Brazilian Patent Office in Brazilian Patent Application No. BR112015023044-0 with English translation (8 total pages).
[cited by applicant]
No Author, “CAS registry No. 189279-58-1—Delafloxacin,” last retrieved on Jan. 5, 2024 from https://www.sigmaaldrich.com/US/en/product/sigma/sml1869 (2 total pages).
[cited by applicant]
No Author, “CAS registry No. 352458-37-8—ABT-492 MegluMine,” last retrieved Jan. 5, 2024 from https://www.chemicalbook.com/ChemicalProductProperty_EN_CB92666618.htm (3 total pages).
[cited by applicant]
No author, “CAS registry No. 6284-40-8—N-Methyl-D-glucamine,” last retrieved Jan. 5, 2024 from https://commonchemistry.cas.org/detail?cas_rn=6284-40-8&search=6284-40-8 (3 total pages).
[cited by applicant]
No author, “CAS registry No. 869884-78-6—Radezolid,” last retrieved Jan. 5, 2024 from https://commonchemistry.cas.org/detail?cas_rn=869884-78-6&search=869884-78-6 (3 total pages).
[cited by applicant]
Takahata, M., “In Vitro and In Vivo Antimicrobial Activities of T-3811ME, a Novel Des-F(6)-Quinolone,” Antimicrobial Agents and Chemotherapy, vol. 43, No. 5, pp. 1077-1084 (May 1999).
[cited by applicant]
U.S. Department of Health and Human Services—Food and Drug Administration, “Draft Guidance for Industry on Acute Bacterial Skin and Skin Structure Infections: Developing Drugs for Treatment; Availability,” Federal Regis…
[cited by applicant]
Search and Examination Report prepared by Korean Intellectual Property Office and issued by United Arab Emirates Patent Office on Nov. 7, 2023 in United Arab Emirate Patent Application No. P1258/15 (12 total pages).
[cited by applicant]
Request for Invalidation filed Nov. 29, 2024 with Taiwanese Patent Office against Taiwanese Patent No. I641372 with English summary (139 total pages).
[cited by applicant]